Showing results (1-10 of 63) with videos related to
Sort By:
Pageof 7
Acta Pharmacologica Sinica|December 4, 2019
CRISPR-cas9: a powerful tool towards precision medicine in cancer treatmentHui Xing, Ling-Hua MengActa Pharmacologica Sinica|August 29, 2007
Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generationLing-hua Meng, Jian DingActa Pharmacologica Sinica|September 17, 2020
Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunityPu Sun, Ling-Hua MengActa Pharmacologica Sinica|November 23, 2021
The double faced role of xanthine oxidoreductase in cancerMan-Man Chen, Ling-Hua MengActa Pharmacologica Sinica|August 25, 2015
Toward rapamycin analog (rapalog)-based precision cancer therapyLing-hua Meng, X F Steven ZhengActa Pharmacologica Sinica|September 15, 2015
PI3K isoform-selective inhibitors: next-generation targeted cancer therapiesXiang Wang, Jian Ding, Ling-hua MengBiochimie|December 13, 2006
Mitochondrial topoisomerases and alternative splicing of the human TOP1mt geneHongliang Zhang, Ling-Hua Meng, Yves PommierCurrent Topics in Medicinal Chemistry|February 7, 2003
Non-camptothecin DNA topoisomerase I inhibitors in cancer therapyLing-Hua Meng, Zhi-Yong Liao, Yves PommierExpert Opinion on Investigational Drugs|February 10, 2010
New microtubule-inhibiting anticancer agentsSi-Meng Chen, Ling-Hua Meng, Jian DingActa Pharmacologica Sinica|April 6, 2018
Oncogene-induced senescence: a double edged sword in cancerXue-Ling Liu, Jian Ding, Ling-Hua MengPageof 7